Prevalence of Non-Responders to Both Oral Bisphosphonate Monotherapy and Intravenous Ibandronate in Patients with Postmenopausal Osteoporosis
نویسندگان
چکیده
منابع مشابه
Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
Osteoporosis is a major healthcare problem that continues growing as the population ages. Sufferers become increasingly susceptible to fractures, which compromise physical and emotional health and increase healthcare costs. Bisphosphonates are the most widely used medicines for the treatment and prevention of postmenopausal osteoporosis. However, therapeutic adherence is suboptimal, meaning tha...
متن کاملIbandronate in the Management of postmenopausal Osteoporosis
Oral daily and weekly bisphosphonates were considered, for several years, as the mainstay for the treatment of postmenopausal osteoporosis. However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long-term, hence outcomes. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedul...
متن کاملQuarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
Osteoporosis is a chronic condition that generally requires long-term therapy for fracture risk reduction to become apparent. Although the bisphosphonates have made a major contribution to how clinicians manage osteoporosis, compliance with therapy has generally been less in the real-world setting than seen in clinical trials. Less-frequently administered dosage regimens or nonoral routes may e...
متن کاملOnce-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
CONTEXT Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. DESIGN, SETTING, AND OBJECTIVES: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (Q...
متن کاملPatient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
OBJECTIVE CURRENT, a large, open-label, 6-month, multicenter study, was designed to assess patient satisfaction levels and patient treatment preference after switching from weekly oral bisphosphonates to monthly oral ibandronate for a period of 6 months. METHODS This study enrolled postmenopausal women who had taken a weekly oral bisphosphonate for at least 3 months for prevention or treatmen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Open Journal of Orthopedics
سال: 2020
ISSN: 2164-3008,2164-3016
DOI: 10.4236/ojo.2020.103007